You are here

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Last updated on June 5, 2019

FOR MORE INFORMATION
Study Location
LA BioMed at Harbor-UCLA Medical Center
Torrance, California, 90502 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

All subjects:

1. Male or female from 18 years of age

2. Provision of informed consent

3. Confirmed diagnosis of HAP/VAP or cIAI requiring iv antibiotic treatment

4. Female patients are authorized to participate in this clinical study if criteria
concerning pregnancy avoidance stated in the protocol are met and negative pregnancy
test

Additional for cIAI:

1. Diagnosis of cIAI, EITHER:

Intra-operative/postoperative enrolment with visual confirmation of cIAI. OR
Preoperative enrollment with evidence of systemic inflammatory response, physical and
radiological findings consistent with cIAI; confirmation of cIAI at time of surgery
within 24 hours of study entry

2. Surgical intervention within 24 hours (before or after) the administration of the
first dose of study drug

Additional for HAP/VAP:

1. Onset symptoms > 48h after admission to or care facility

2. New or worsening infiltrate on CXR or CT scan

3. Clinical signs and symptoms and laboratory findings consistent with HAP/VAP

4. Respiratory specimen obtained for Gram stain and culture following onset of symptoms
and prior to randomisation

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

All subjects:

1. APACHE II score > 30

2. Confirmed or suspected infection caused by Gram-negative species not expected to
respond to study drug, or Gram-positive species

3. Receipt of >24 hr systemic antibiotic within 48h prior to randomisation (exception in
case of treatment failure)

4. History of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious
reaction to aztreonam, carbapenem,monobactam or other ?-lactam antibiotics, avibactam,
nitroimidazoles or metronidazole, or any of the excipients of the study drugs

5. Known Clostridium difficle associated diarrhoea

6. Requirement for effective concomitant systemic antibacterials or antifungals

7. Creatinine clearance ?15 ml/min or requirement or expectation for renal replacement
therapy

8. Acute hepatitis, cirrhosis, acute hepatic failure, chronic hepatic failure

9. Hepatic disease as indicated by AST or ALT >3 × ULN. Patients with AST and/or ALT up
to 5 × ULN are eligible if acute and documented by the investigator as being directly
related infectious process

10. Patient has a total bilirubin >2 × ULN, unless isolated hyperbilirubinemia is directly
related to infectious process or due to known Gilbert's disease

11. ALP >3 × ULN. Patients with values >3 × ULN and directly related to the infectious process being treated

12. Absolute neutrophil count

13. Pregnant or breastfeeding or if of child bearing potential, not using a medically
accepted effective method of birth control.

14. Any other condition that may confound the results of the study or pose additional
risks to the subject

15. Unlikely to comply with protocol

16. History of epilepsy or seizure disorders excluding febrile seizures of childhood

Additional for cIAI

1. Diagnosis of abdominal wall abscess; small bowel obstruction or ischemic bowel disease
without perforation; traumatic bowel perforation with surgery within 12 hours of
diagnosis; perforation of gastroduodenal ulcer with surgery primary etiology is not likely to be infectious

2. Simple cholecystitis, gangrenous cholecystitis without rupture, simple appendicitis,
acute suppurative cholangitis, infected necrotizing pancreatitis, pancreatic abscess

3. Prior liver, pancreas or small-bowel transplant

4. Staged abdominal repair (STAR), open abdomen technique or marsupialisation

Additional for HAP/VAP

1. APACHE II score

2. Known or high likelihood of Gram-positive monomicrobial infection

3. Lung abscess, pleural empyema, post-obstructive pneumonia

4. Lung or heart transplant

5. Myasthenia gravis

NCT03329092
Pfizer
Suspended
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now